The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

“AI can help us to find patterns in data and, increasingly ... AI is increasingly being explored by most big pharmaceutical companies eager to advance their own programs and accelerate the pace of ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

By combining diverse datasets and powerful analytical and modeling tools, drug developers are finding more potential ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

We recently published a list of 13 AI News and Ratings You Probably Missed. In this article, we are going to take a look at ...

Selected preclinical small molecule candidates will now be tested through the Quris-AI platform prior to initiating clinical trials. This follows a successful two-year validation study with Merck KGaA ...

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.

Finding new medicines has always been a long, expensive, and complicated process. Scientists need to identify the right targets in the body, test thousands of potential compounds, and spend years in ...

All of them reduce fractures by 30–70%, depending on the site of the fracture and the drug. Most of our drugs ... are Phase II data showing it reduces bone breakdown while allowing bone formatio ...